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Vascular endothelial growth factor (VEGF), a pluripotent cytokine and angiogenic 
growth factor, plays crucial roles in embryonic development and tumour 
progression, and is over-expressed in many types of cancer and generally 
associated with tumour progression and survival rate. The polypurine/polypyrimide 
sequence located upstream of the promoter region of the human VEGF gene that 
can form specific G-quadruplex structures and raise the possibility for 
transcriptional control of the VEGF by G-quadruplex ligands. In the present study, 
we investigated the interaction between the 5-N-methyl-7-fluorine-quindoline 
derivatives and the G-rich sequence in VEGF’s promoter and the subsequent 
effects on the biological functions of VEGF. We found the strong interaction 
between the 5-N-methyl-7-fluorine-quindoline derivatives and the G-rich DNA of 
VEGF, and this interaction might significantly influence the biological functions of 
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VEGF, including the transcription and expression of VEGF, cell proliferation and 
apoptosis, and the stimulation of angiogenesis in chick embryo. 
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Introduction 
Vascular endothelial growth factor (VEGF), a pluripotent cytokine and angiogenic growth 
factor, plays crucial roles in embryonic development, which acts as a potent inducer of 
vascular permeability, a survival and mitogen factor for endothelial cells in adults. At the 
same time, the starving tumour cells need the formation of new blood vessels to supply 
necessary oxygen and nutrients, and newly formed blood vessels serve as escape routes 
for disseminating tumour cells. Since the angiogenic switch in tumour cells is often 
initiated by increased expression of VEGF, resulting in VEGF over-expressed in many 
types of cancer and generally associated with tumour cells progression and survival rate 
(Duda et al., 2007). Some of anti-VEGF medicines with variant working mechanisms have 
entered clinical practices for the therapy of cancer, such as Bevacizumab (Hurwitz et al., 
2004; Kramer and Lipp, 2007; Sandler et al., 2007), Sorafenib (Escudier et al., 2007) and 
sunitinib (Chu et al., 2007; Motzer et al., 2007). 
Guanine-rich （G-rich）stretches of DNA have a high propensity to self-associate into 
planar guanine quartets (G-quartets) to give unusual structures called G-quadruplexes 
(Figure 1). As guanine-rich sequences exist in important regions of the eukaryote genome 
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such as the telomere and the regulation region of many genes, such structures may play 
important roles in the regulation of biological events in the body. Therefore 
G-quadruplexes have become valid targets for new anti-cancer drugs in the past few 
decades (Ou et al., 2008). The polypurine/polypyrimide sequence located upstream (-89 
to -43) of the promoter region of the human VEGF gene, which serves as a multiple 
binding site for transcription factors, such as Sp1 and Egr-1, consists of five runs of at 
least three contiguous guanines. This tract can form specific G-quadruplex structures and 
raise the possibility for transcriptional control of the VEGF by G-quadruplex ligands (Sun 
et al., 2005). Since the expression of human VEGF is mainly regulated at the 
transcriptional level (Bikfalvi and Bicknell, 2002; Martiny-Baron and Marme, 1995), 
designing drugs targeting VEGF via stabilizing G-quadruplex in its promoter region seems 
to be a potent strategy. 
Quindoline derivatives had been proved to be valid G-quadruplex ligands and to interact 
with human telomere or c-myc oncogene, and showed effects on the biological functions 
of these two genes, including extension of telomere, cell proliferation, cell senescence 
and apoptosis, and also could down-regulate the transcription of c-myc (Liu et al., 2007; 
Ou et al., 2007; Zhou et al., 2005; Zhou et al., 2006). The previous studies indicated that 
the 11-alkylamines group of quindoline could provide the in situ protonation to the 5-N 
atom. However, the positive charge of the 5-N atom was unstable in different buffer 
conditions. Thus, the strategy of N-methylation at 5-position was applied to introduce a 
stable positive charge for the electrostatic interaction and to increase π-stacking 
interaction as a result of the reduction of the electron density of the aromatic core of ligand. 
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In addition, one fluorine substituent was introduced on 7-position to improve the ability to 
stack onto the G-quadruplex (Figure 2).  
In the present study, we investigated the interaction between the 
5-N-methyl-7-fluorine-quindoline derivatives and the G-rich sequence in VEGF’s promoter 
and the subsequent effects on the biological functions of VEGF. We found that strong 
interaction between the 5-N-methyl-7-fluorine-quindoline derivatives and the G-rich DNA 
of VEGF, and this interaction might significantly influence the biological functions of VEGF, 
including the transcription and expression of VEGF, cell proliferation and apoptosis, and 
the stimulation of angiogenesis in chick embryo. 
 
Results 
Stabilization of G-quadruplex in VEGF’s promoter region by 
5-N-methyl-7-fluorine-quindoline derivatives 
To evaluate the interaction between the G-rich sequence in VEGF’s promoter (oligomer 
PuT, 5’-TTTTTGGGCGGGCCGGGGGCGGGTTTTT-3’) and the quindoline derivatives, 
PCR stop assay was used as a quantitative method for screening the ability of the 
derivatives in blocking DNA amplification (Lemarteleur et al., 2004). The results might 
indicate the binding of derivatives to the DNA, or the ability in stabilizing the 
G-quadruplexes. SYUIQ-05 and the four 5-N-methyl-7-fluorine-quindoline derivatives 
(Figure 2) were used in this assay. As shown in Figure 3 (A to E), the amount of 
double-stranded PCR products decreased with the increasing concentration of all the 
derivatives, indicating that they could block the formation of PCR products at certain 
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concentration. To further demonstrate the inhibitory effects of the derivatives on the 
G-quadruplex stabilization of PuT, a control oligomer PuTmu 
(5'-TTTTTGGGCGAACCGGGGGCGGGTTTTT-3'), which could not form the 
G-quadruplex structure, was included in this assay. Under the same condition, no 
inhibition was observed even at the highest concentration of 50 μM with this control 
oligomer (Figure 3F). 
For easy comparison, the ligand concentrations that decreased the amount of PCR 
product by 50% (the IC50 values) were calculated using the optical density values from the 
gel photos. All the screened derivatives showed higher inhibitory effects on the 
amplification of the oligomer PuT, with IC50 values of 4.9 ± 1.2 μM (SYUIQ-FM04), 1.0 ± 
0.4 μM (SYUIQ-FM05), 6.3 ± 1.0 μM (SYUIQ-FM06), and 7.2 ± 0.6 μM (SYUIQ-FM07), 
respectively. While the IC50 value of SYUIQ-05 was 16.6 ± 0.7 μM, which implied that the 
introduction of 5-N-methyl and 7-fluorine atom in quindoline could enhance the interaction 
between G-quadruplex DNA and the derivatives. Among them, the derivative 
SYUIQ-FM05 with an N,N-dimethyl-propane-1,3-diamine side chain showed a strongest 
interaction with PuT, hence it was chosen as the leading derivatives for the following 
studies. 
To further investigate the effects of the derivatives on the G-quadruplex in VEGF’s 
promoter region, circular dichroism (CD) spectra was performed to identify the 
conformation of G-quadruplex DNA PuT. Figure 4A showed the results of CD titration 
assay, in which the G-DNA PuT was titrated with SYUIQ-FM05. In the absence of cation, 
the oligomer PuT showed one broad positive peaks at around 280 nm and a minor 
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shoulder at around 260 nm, which indicated that this G-DNA might exist as a mixture of 
different G-quadruplex structures. Upon addition of SYUIQ-FM05 to the 
G-quadruplex-preformed PuT (Figure 4A), the pattern of CD spectra changed with 
decrease of the minor shoulder at 260 nm and the band shifting from 280 nm to 277 nm, 
which indicated that the derivative could interact with the DNA. In addition, the thermal 
stability of this G-quadruplex DNA was enhanced by SYUIQ-FM05 with the increasing Tm 
value (from 40 oC to 55 oC). The CD results indicated that the derivative SYUIQ-FM05 had 
the ability to interact with the G-quadruplex DNA in VEGF, resulting in the increasing 
thermal stabilities of DNA. 
 
Down-regulation of the transcription and expression level of VEGF by SYUIQ-FM05 
The transcription of the VEGF gene might be regulated by forming the G-quadruplex 
structures in the G-rich sequence of its promoter region, resulting in blocking the 
interaction of transcriptional factors with their cognate sites (Sun et al., 2005).  The 
influences of SYUIQ-FM05 on the transcription and expression of VEGF were evaluated 
by RT-PCR and Western blot (Figure 5). The expression of VEGF decreased dramatically 
in both mRNA and protein levels after the HL-60 cells were treated with SYUIQ-FM05 for 
2 days. 
 
Inducing of the HL-60 cells to apoptosis by SYUIQ-FM05 
In human tumour cells, the microenvironment was normalized by the reduction of the 
excess abnormal vasculature and cell apoptosis increased by the anti-VEGF agent 
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(Willett et al., 2004; Willett et al., 2005). HL-60 apoptosis induced by SYUIQ-FM05 was 
determined by monitoring cellular proteins caspase-3 and PARP in Western blot. It was 
well known that caspase-3, a major executor of apoptosis, mediated cleavage of many 
substrates, including PARP (Saraste and Pulkki, 2000; Soldani and Scovassi, 2002). 
Figure 6E showed that PARP was cleaved to an 89 kDa fragment after cells were treated 
with 0.2 μM SYUIQ-FM05 for 4 days. As the derivatives concentration increased, 
cleavage of pro-caspase-3 (35 kDa) was observed, inferred by the weakening of the band 
of 35 kDa. However, the caspase-3 fragmentations of 17 kDa were not detected probably 
due to low protein concentration. 
Apoptosis could also be evaluated by flow cytometry (Crissman and Steinkamp, 1973). 
The percentage of sub-G1 peak, representing the population of apoptosis cells, increased 
from 3% to 23% after derivative treatment (Figure 6A to 6D). The results showed that 
SYUIQ-FM05 had significant ability to induce HL-60 cell apoptosis. 
In addition, SYUIQ-FM05 could also show significant inhibitory effect on the proliferation 
of HL-60 cells, either in the short-term proliferation and the long-term proliferation assay 
(Data not shown).  
 
Inhibition of the angiogenesis in chick embryo chorioallantoic membrane BY SYUIQ-FM05 
VEGF was well known as vascular permeability factor, and the VEGF related 
antibodies had been proved to block angiogenesis in the Chick Embryo Chorioallantoic 
Membrane Model (CAM) (Arora et al., 1999; Ramakrishnan et al., 1996). The 
anti-angiogenic potentials of the quindoline derivatives were identified on CAM by adding 
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the SYUIQ-FM05 directly into the choroallantoic membrane for determining their inhibitory 
effects on the blood vessels growth. Figure 7 showed the microscopy images of the new 
blood vessels in chorioallantoic membrane and the inhibitory response of the drugs. 
Comparing to the blank sample (0.9% NaCl), SYUIQ-FM05 showed a significant effect on 
the reduction of the blood vessels, even stronger than the control drug of Thalidomide. 
 
Down-regulation of expression of VEGF by SYUIQ-FM05 was related to the inhibition of 
angiogenesis 
To identify whether the down-regulation of expression of VEGF by SYUIQ-FM05 that was 
related to the inhibition of angiogenesis, the protein extracts from the medium used in the 
Western blot were subsequently performed the CAM assay. As shown in Figure 8, the 
blood vessels in the choroallantoic membrane treated with the medium extracts of normal 
HL-60 cells increased, because the VEGF proteins was able to stimulate the growth of 
blood vessels (Figure 8, ‘control’ column). In contrast, the blood vessels did not show this 
stimulated growth when incubated with the medium extracts of the drug treated cells 
(Figure 8). This finding indicated that the down-regulation in expression of VEGF by the 
quindoline derivatives might play an important role in the inhibition of the angiogenesis. 
 
Discussion  
VEGF is a pluripotent cytokine and angiogenic growth factor (Goodsell, 2003). When it 
binds with its cognate receptor, the complex can stimulate the proliferation, migration, 
survival, and permeability of endothelial cells, thus resulting in the formation of new blood 
 9
vessels (Rak and Yu, 2004). The formation of new blood vessels adjacent to primary 
tumours promotes the growth of tumour cells by providing oxygen and nutrients. Because 
VEGF can initiate angiogenesis to aid in tumour cell survival, and its expression is usually 
elevated in many types of cancer (Bikfalvi and Bicknell, 2002). Additional, 
VEGF-dependent actions include increased vascular permeability, paracrine/autocrine 
growth factor release, resulting in enhancement of cell motility and inhibition of apoptosis 
(Epstein, 2007). The phenomenon not only occurred in endothelial cells, but also in 
hematopoietic cells, stromal cells, and malignant cells in certain human cancers(Ellis, 
2006; Fan et al., 2005; Wedam et al., 2006; Wey et al., 2005), such as the HL-60 cells 
used in the present work. 
G-quadruplex, the stacking of tetrameric arrangement of guanines, has been 
considered as targets for antitumor drug design in recent years (Hurley, 2001). This 
special DNA secondary structure exists in some gene promoter region (Dexheimer et al., 
2006; Siddiqui-Jain et al., 2002; Sun et al., 2005) and act as transcription regulator 
(Siddiqui-Jain et al., 2002). The transferring from duplex to quadruplex conformation in the 
promoter region of VEGF can be driven by G-quadruplex ligands such as TMPyP4 and 
telomestatin, and resulting in affect the enzymes bind to this region (Sun et al., 2005), 
indicating that the formation of G-quadruplexes may play a role in VEGF expression.  
5-N-methyl-7-fluorine-quindoline derivatives showed strong interaction with the G-rich 
DNA in VEGF’s promoter. The interactions mainly involved stabilizing the G-quadruplex 
structure of the VEGF’s promoter DNA (CD melting data), and blocking the amplification 
of G-rich DNA catalyzed by Taq polymerase (PCR stop assay data). Subsequently, the 
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down-regulation of transcription and expression of VEGF by SYUIQ-FM05 were evaluated 
by RT-PCR and Western blot. SYUIQ-FM05 showed a significant inhibitory activity on 
both the transcription and expression of VEGF, indicating that this G-quadruplex ligand 
might regulate the transcription of gene via the stabilizing of G-quadruplex.  
5-N-methyl-7-fluorine-quindoline derivatives showed significant effects on related 
biological functions of VEGF, including the angiogenesis of embryo, the apoptosis caused 
by the change of blood vessels, and tumour cell proliferation. Obviously, from the data in 
CAM assay, the SYUIQ-FM05 showed strong inhibitory activity on the growth of blood 
vessels, and this inhibition effect might come from the down-regulation of the expression 
of VEGF by SYUIQ-FM05. In addition, this derivative could also induce apoptosis in 
leukemia cells and inhibit cell proliferation.  
These results supported the hypothesis that the 5-N-methyl-7-fluorine-quindoline 
derivatives could stabilize the G-quadruplex structures formed in the promoter region of 
VEGF gene in vitro and thus inhibit angiogenesis in embryo and induce apoptosis of 
tumour cells. Moreover, angiogenesis and apoptosis are complicated intracellular 
program, controlling by many intrinsic and extrinsic factors. Thus, it was hard to ascertain 
that VEGF gene G-quadruplex was the only reason for blood vessels growth inhibition, but 
it could be one of the important elements. 
In conclusion, VEGF is a crucial gene in the angiogenesis and tumour progress. The 
forming or stabilizing of the G-quadruplex structure in its promoter region may play a role 
in the regulation of this gene. The quindoline derivatives, especially the 
5-N-methyl-7-fluorine-quindoline derivatives, showed strong interaction with the 
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G-quadruplex DNA of VEGF and resulting in down-regulation of the transcription and 
expression of this gene and potentially reduced the angiogenesis simulated by VEGF. 
 
Materials and methods 
Materials. The oligomers/primers used in this study were purchased from Invitrogen 
(China). Anti-VEGF, anti-Caspase-3, and anti-PARP primary antibody and horseradish 
peroxidase-conjugated anti-mouse or anti-rabbit secondary antibody were purchased 
from Chemicon International, Inc., USA. Anti-β-actin primary antibody was purchased 
from Jingmei Biotech, China. Fertilized chicken eggs were purchased from South China 
Agricultural University. 
To eliminate the problem of mixed of intra- and intermolecular structures caused by the 
large size of DNA fragments, a truncated sequence (named as PuT) from the VEGF’s 
promoter region that contains only those runs of guanines involved in the intramolecular 
G-quadruplexes was used in all the assays. The sequence was 
5’-TTTTTGGGCGGGCCGGGGGCGGGTTTTT-3’ (Sun et al., 2005). 
 
Preparation of Compounds. The key intermediates of 11-chloro- quindoline 3 was 
prepared following the procedure reported (Bierer et al., 1998). The selective N-5 
methylation of 11-chloroquindoline with iodomethane was achieved in the presence of 
sulpholane. Sulpholane was reported as a solvent for certain N-quarternization reactions 
that were used for selective N-alkylation of quindoline (Fan and Ablordeppey, 1997). The 
substitution reaction of compounds 3 and compounds 4 with various alkylamines gave the 
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final products of 11-amino-5-N-methyl-7-fluorine-quindoline derivatives (Scheme 1). All 
the substitution reactions were completed in high yields (80–92%) within 30 min. All of the 
compounds were identified by NMR, high-resolution mass spectra and elemental 
analyses. 
All the derivatives were made as 10 mM stock solution in DMSO. The positive drug 
Thalidomide was purchased as a standard substance from the National Institute for the 
Control of Pharmaceutical and Biological Products and also made as 10 mM stock 
solution in DMSO. Further dilutions to working concentrations were made in 
double-distilled water. 
 
PCR Stop Assay. The reaction were performed in 1×PCR buffer, containing 2 μmol of a 
pair of oligomers, which were PuT or PuTmu 
(5’-TTTTTGGGCGAACCGGGGGCGGGTTTTT-3’) and the corresponding 
complementary sequence PuTrev (5’-ATCGCTTCTCGTAAAAACCC-3’), 0.16 mM dNTP, 
2.5 U Taq polymerase and a certain concentration of the derivatives. Reaction mixtures 
were incubated in a Mastercycler Personal® (Eppendorf) with the following cycling 
conditions: 94 °C for 3 min, followed by 10 cycles of 94 °C for 30 s, 58 °C for 30 s, and 72 
°C for 30 s. Amplified products were resolved on 15% non-denaturing polyacrylamide gels 
in 1×TBE and EtBr-stained.  
 
Circular Dichroism Spectrum. The oligomer PuT at a final concentration of 5 μM was 
resuspended in Tris-HCl buffer (10 mM, pH 7.4) containing the derivatives to be tested. 
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The samples were heated to 95 °C, then gradually cooled to room temperature, and 
incubated at 4 °C for at less 6 h. The CD spectra were recorded on a Chirascan 
(AppliedPhotophysics), using 0.5s-per-points from 200 to 400 nm and 1 nm bandwidth. In 
the melting studies, the sample temperature was maintained by a Pelter temperature 
controller. The melting curves of the G-quadruplex were measured at 280 nm. Before the 
CD spectra measurement, all the samples were thermally treated as described above.  
 
Cell Lines and Drug Treatments. The human leukemia cells HL-60 were obtained from the 
American Type Culture Collection (ATCC) (Rockville, MD). The cell lines were maintained 
in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml 
penicillin and 100 μg/ml streptomycin in 25-cm2 culture flasks at 37 °C humidified 
atmosphere with 5% CO2. All cells to be tested in the following assays had a passage 
number of 3–6. About 5×105 cells were seeded into 6-well plates and incubated with the 
medium-diluted derivatives and incubated for 2 or 4 days.  
 
RNA Extraction. Cell pellets harvested from each well of the culture plates were lysed in 
TRIzol solution. Total RNA was extracted according to the protocol supplied by the Takara 
Company and eluted in distilled, deionized water with 0.1% diethyl pyrocarbonate (DEPC) 
to a final volume of 50 μl. RNA was quantitated spectrophotometrically and stored at -80 
°C. 
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RT-PCR. Total RNA was used as a template for reverse transcription using the following 
protocol: each 20-μl reaction contained 1× M-MLV buffer, 500 μM dNTP, 100 pmol oligo 
dT18 primer, 100 unit of M-MLV reverse transcriptase, DEPC-H2O, and 1 μg of total RNA. 
Mixtures were incubated at 42 °C for 60 min for reverse transcription and then at 92 °C for 
10 min. PCR was performed according to the following protocol: each 20-μl reaction 
contained 1× PCR buffer, 500 μM dNTPs, 1.5 μM primers pair, 1 unit of Taq polymerase, 
0.1% DEPC-H2O, and 3 μl of the cDNA template. The reactions were incubated in a 
Mastercycler Personal (Eppendorf) as follows: 95 °C for 5 min, followed by 36 cycles of 95 
°C 1 min, 50 °C (or 58 °C for bcl-2) for 1 min, and 72 °C for 1min. The amplified products 
were separated on a 1.5% agarose gel and the gel was photographed on a Gel Doc 2000 
Imager System. 
  The primers used in the PCR were: VEGF165A 
(5’-AACATATGGCACCCATGGCAGAAGGAGG-3’), VEGF165S 
(5’-AAGGATCCGCGGCCGCTATCACCGCCTCGGCTTGTC-3’), β-actin A 
(5’-GTTGCTATCCA GGCTGTGC-3’), and β-actin S (5’-GCATCCTGTCGCCAATGC-3’). 
 
Protein Extraction. Cells harvested from each well of the culture plates were lysed in 150 
μl extraction buffer consisting of 100 μl solution A (50 mM glucose, 25 mM Tris-HCl, pH 8, 
10 mM EDTA, 1 mM PMSF) and 50 μl solution B (50 mM Tris-HCl, pH 6.8, 6 M urea, 6% 
2-mercaptoethanol, 3% SDS, 0.003% bromphenolblue). The suspension was centrifuged 
at 10,000 rpm at 4°C for 5 min. The protein concentration in this supernatant and the cell 
culture media from each well was quantitated according to BCA quantitation protocol. 
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Western Blot. The protein extracts were loaded onto 10% polyacrylamide gel and then 
transferred to a microporous polyvinylidene difluoride (PVDF) membrane. Western blot 
was performed using anti-VEGF (extracts from the medium) or anti-β-actin, 
anti-Caspase-3, or anti-PARP (extracts from the cells) antibody and horseradish 
peroxidase-conjugated anti-mouse or anti-rabbit secondary antibody. Proteins were 
visualized using chemiluminescence substrate. 
 
Flow Cytometry Analysis. 106 Cells were washed with ice-cold PBS and fixed in 75% 
ethanol at -20  for at least 1 h. After that, cells were washed twice, incubated with 0.5 
mg/ml RNase A, and stained with 10 μg/ml PI. Fluorescence emitted from the PI-DNA 
complex was quantitated by Epics Elite flow cytometry (Beckman-Coulter). 
 
Blood vessels counting in CAM. The construction of CAM and blood vessel counting were 
performed according to the reference (Ribatti et al., 2000). In brief, fertilized chicken eggs 
were placed in an incubator as soon as embryogenesis started and were kept under 
constant humidity at 37 oC. On day 8, a square window was opened in the shell after 
removal of 2-3 ml of albumen to detach the CAM from the shell. Substances with testing 
compounds or protein extracts from cells treated with testing compounds were added to 
the detached the CAM. The window was sealed with a parafilm and incubated for 3 days. 
The embryo and its extraembryonic membranes were transferred to a patri-dish and fixed 
with formalin. The fixed sections were photographed under a microscope and the vessel 
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number and density were determined by two independent observers and the data was 
analysed statistically. 
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Titles and legends to figures 
Figure 1 The quadruplex structure and the G-quartet surface. 
 
Figure 2 Structures of the 11-amino-5-N-methyl-7-fluorine- quindoline derivatives. 
 
Figure 3 Effects of 11-amino-5-N-methyl-7-fluorine- quindoline derivatives on the DNA 
amplification of the G-quadruplex forming oligomer PuT in the PCR stop assay. Control 
oligomer PuTmu (F) was also used in this assay with all the derivatives. Increasing 
concentrations of derivatives (0-20.0 μM) were added to G-quadruplex forming PuT 
oligomer, or all the derivatives at 50 μM were added to mutated PuTmu oligomers and the 
40 bp double-stranded PCR products were separated on 15% non-denaturing 
polyacrylamide gels in 1×TBE and EtBr-stained.  
 
Figure 4 (A) CD spectra of PuT/ligand complexes incubated with different ratio. All of the 
spectra were collected in a strand concentration of 5 μM using 2 mm path length quartz 
cuvette in 10 mM Tris-HCl buffer, pH 7.4. The ratio of PuT:ligand was 1:0 (solid line), 1:1 
(●), 1:2 (), and 1:3 (＊). (B) CD melting profiles of PuT in the absence of ligands or in the 
presence of 15 μM SYUIQ-FM05. 
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Figure 5 The transcription/expression of VEGF in HL-60 cells incubated with 
SYUIQ-FM05. The transcription of the VEGF gene was determined using the RNAs 
extracted from the treated HL-60 cells by RT-PCR (A) and the expression of the VEGF 
gene was determined using the proteins from the medium of the treated HL-60 cells (for 
VEGF) or the proteins from the treated HL-60 cells (for β-Actin) by Western blot (B). 
 
Figure 6 Apoptosis of HL-60 cells induced by SYUIQ-FM05. HL-60 cells were treated with 
no drug (A), 0.05 μM (B), 0.1 μM (C), and 0.2 μM (D) SYUIQ-FM05 for 4 days, and then 
analyzed by flow cytometry. The M value represented the percent of apoptotic cells. (E) 
Cleavage of Caspase-3 and PARP of HL-60 cells treated with 0.02, 0.05, 0.1, and 0.2 μM 
SYUIQ-FM05 for 4 days. 
 
Figure 7 The results of CAM assay. 750 ng/10 μl of SYUIQ-FM05 were added directly into 
the choroallantoic membrane and incubated for 3 days. The blood vessels were counted 
under a microscope (4 ×) and the percentage of inhibitory response was plotted. 0.9% 
NaCl was used as a negative control (blank) and thalidomide (treatment at the 
concentration of 1500 ng/10 μl) as a positive control. Each assay was repeated in 8-10 
samples. 
 
Figure 8 The results of CAM assay using protein extracts from treated cells. 0.5 μM of 
SYUIQ-FM05, and 12.5 μM (positive-high) or 0.5 μM (positive-low) of Thalidomide were 
added directly into the HL-60 cells, after 48h incubation, the proteins were extracted from 
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the medium and quantitated. The extracted proteins were added into the choroallantoic 
membrane and incubated for 3 days. The blood vessels were counted under a 
microscope and the percentage of stimulated response was plotted. 0.9% NaCl was used 
as a blank and the protein extracts from the untreated cells were used as a control. Each 
assay was repeated in 8-10 samples.  
 
Scheme 1.  Synthesis of 5-N-Methyl 11-amino-5-N-methyl-7-fluorine- quindoline 
derivatives a 
a Reaction Conditions: (a) CH3I, sulpholane, 55oC, overnight; (b) substituted alkylamine, 
2-ethoxyethanol, 120 °C, 30 min. 
 
 
 








